Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.66 |
| ▸ | CCND1 | P24385 | 18/20 | 0.66 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.66 |
| ▸ | CDK2 | P24941 | 5/20 | 0.66 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.66 |
| ▸ | CDK9 | P50750 | 4/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.66 |
| ▸ | CCND3 | P30281 | 13/20 | 0.59 |
| ▸ | CCND2 | P30279 | 9/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19294159 | 0.85 | CDK4 (0.64) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL22558085 | 0.85 | CCND1 (0.52) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL28404189 | 0.84 | CDK4 (0.63) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL13202797 | 0.83 | CDK4 (0.52) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL29671046 | 0.83 | CDK4 (0.62) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL18788069 | 0.83 | CDK4 (0.62) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL4833350 | 0.83 | CDK4 (0.62) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL23913121 | 0.82 | CDK4 (0.61) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL19021358 | 0.81 | CDK4 (0.60) | CDK4CCND1CDK6CDK2CCNT1 | |
| SCHEMBL18806093 | 0.81 | CDK4 (0.71) | CDK4CCND1CDK6CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220024916-A1 | HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-11225492-B2 | Heterocycles useful as anti-cancer agents | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3386981-B1 | HETEROCYCLES USEFUL AS ANTI-CANCER AGENTS | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2017101763-A1 | HETEROCYCLES USEFUL AS ANTI-CANCER AGENTS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024916-A1 | HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | HDAC1, HDAC3, HDAC2 | CDK4 16/4885CCND1 88/4885CDK6 5/4885 |
| US-11225492-B2 | Heterocycles useful as anti-cancer agents | TP53, VHL, ABCG2 | CDK4 9/4885CCND1 42/4885CDK6 86/4885 |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | CDK4 219/4885CCND1 108/4885CDK6 335/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | CDK4 219/4885CCND1 108/4885CDK6 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.